New approaches pursued on Parkinson's

A team of scientists say they have developed a drug that blocks the SIRT2 enzyme, which protects the neurons damaged by Parkinson's disease. In an article to come out this week in the journal Science, researchers at Harvard show how inhibition of SIRT2--a member of the sirtuin family, which is linked to aging--prevents the toxicity of the protein aggregates that are believed to be behind the neuronal death characteristic of PD. Contrary to "classic" approaches that try to eliminate these aggregates, SIRT2 inhibition appears to work by "fusing" many small protein aggregates into larger (apparently less neuro-toxic) ones.

In addition, researchers at New York-Presbyterian Hospital/Weill Cornell Medical Center have also used an AAV virus to deliver a gene to the brains of 11 volunteers with Parkinson's disease. The gene is a regulator of GABA, a neurotransmitter. There were no side effects from the therapy and the treatment helped reduce the symptoms of Parkinson's for up to four years.

- see the release on SIRT2
- check out the report from the Daily Herald
- here's the report on AAV work

Suggested Articles

Antibiotics dubbed odilorhabdins (ODLs), inspired by soil-dwelling nematodes, hold promise for treating antibiotic-resistant infections.

A PureTech startup is developing an immune-responsive hydrogel that releases a corticosteroid into arthritic joints based on their level of inflammation.

A trial of a retinal implant built from embryonic stem cells produced encouraging results in patients with dry age-related macular degeneration.